icad (ICAD)
icad Debt to Equity Ratio: 0.4173
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ICAD Debt to Equity Ratio Rankings
| Overall | 46th percentile | 2278 of 4259 |
| Sector | 23rd percentile | 607 of 798 in Technology |
| Industry | 9th percentile | 18 of 20 in Technical & System Software |
ICAD Debt to Equity Ratio Range, Past 5 Years
| Minimum | 0.00 | Sep 2008 |
| Maximum | 0.4173 | Mar 2012 |
| Average | 0.0473 |
About Debt to Equity Ratio
YCharts Calculation: Debt to Equity = (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity
The debt to equity ratio is a leverage ratio indicating the relative proportion of shareholders' equity and debt used to finance a company's assets. It reveals how a company has financed its assets. A low debt to equity ratio indicates lower risk because shareholder's have claims on a larger portion of the company's assets.
A high debt to equity ratio usually means that a company has been aggressive in financing growth with debt and often results in volatile earnings.
It is also known as Debt/Equity Ratio, Debt-Equity Ratio, and D/E Ratio.
Learn More
You may also be interested in these ICAD related companies
ICAD News
$ICAD bought more today @ around .50 cents a share I feel this is a good buy. in 6-12 months i look for the price of this to double.
about 6 hours ago by miestro
about 6 hours ago by miestro
iCAD Announces First European Patients Treated with Xoft Radiation Therapy System
May 10, 12:45PM Benzinga
May 10, 12:45PM Benzinga
REVIEWING THE "I's:" Nice print last week @ L: $IFON & stock's ripped. L: $ICAD print shows mgmt executing but needed better from L: $IPAS.
about 22 days ago by Legacy_Trades
about 22 days ago by Legacy_Trades
Breastlink Medical Group to Offer iCAD’s Xoft Radiation Therapy System to Breast Cancer Patients
May 04, 9:30AM Business Wire
May 04, 9:30AM Business Wire
iCAD to Host First Quarter 2012 Financial Results Conference Call on Tuesday, May 8, 2012
Apr 30, 8:30AM Business Wire
Apr 30, 8:30AM Business Wire
iCAD Launches Post-Market Study of Intra-Operative Radiation Therapy to Treat Early Stage Breast Cancer
Mar 15, 10:00AM Business Wire
Mar 15, 10:00AM Business Wire
iCAD to Host Fourth Quarter 2011 Financial Results Conference Call on Tuesday, February 28, 2012
Feb 21, 6:00PM Business Wire
Feb 21, 6:00PM Business Wire
iCAD Announces Distribution Agreement with Carestream for MR Image Analysis and Mammography CAD
Dec 12, 2:15PM Benzinga
Dec 12, 2:15PM Benzinga
iCAD Showcases Its Computer-Aided Detection and Advanced Image Analysis Solutions at RSNA 2011
Nov 28, 11:09AM Business Wire
Nov 28, 11:09AM Business Wire
hft alert detects big algo activity in ICAD...penny stock hell i guess..$spy $ICAD http://chart.ly/2jrods8
about 190 days ago by HFTAlert
about 190 days ago by HFTAlert
iCAD Announces Recent Adoption of Its Xoft Electronic Brachytherapy System by Leading U. S. Hospitals
Nov 09, 9:43AM Business Wire
Nov 09, 9:43AM Business Wire
Icad, Inc. (ICAD) Posts Narrower than Expected Q3 Loss; Affirms Outlook
Oct 26, 4:50PM Street Insider
Oct 26, 4:50PM Street Insider
$ICAD The price action indicates a troubled stock, however is oversold and could rally. $S has better price action & is much more bullish
about 440 days ago by Spaniard
about 440 days ago by Spaniard
Does anyone have any insight on $icad Everything I read says it's great but the stock says NO?
about 440 days ago by bcarter674
about 440 days ago by bcarter674
iCAD $ICAD to Acquire Xoft for 8.47M Shares, $1M in Cash; Deal Valued at $13.1M
about 530 days ago by Street_Insider
about 530 days ago by Street_Insider
RT @Street_Insider: Icad $ICAD trading halted with news pending
about 530 days ago by aspenheights100
about 530 days ago by aspenheights100
@PaulWeinacht $ICAD FDA approval was not a big deal at the time is the problem.
about 580 days ago by johnwelshtrades
about 580 days ago by johnwelshtrades
@JohnWelshTrades You follow bios pretty closely...have you heard why $ICAD has been beat to hell since FDA approval?
about 580 days ago by paulweinacht
about 580 days ago by paulweinacht
@adamfeuerstein Any expectation on $ICAD? Down huge since FDA approval.
about 620 days ago by paulweinacht
about 620 days ago by paulweinacht
Watching $ICAD present now at Canaccord. Like the story - strong technology, good partners, lot of cancer to diagnose sadly #yam
about 659 days ago by Heuristocrat
about 659 days ago by Heuristocrat
Tough day for $ICAD with profit takers. Will add more if it falls under $2
about 663 days ago by paulweinacht
about 663 days ago by paulweinacht
Stock Breakout Aug 4th: 29 breakouts: $CPSL, $ICAD, $LAZ, $ONCY, $OPEN (stop: $43.49), $OEH (base + 200-day MA).. http://bit.ly/bBRw7Z
about 664 days ago by Fallond_Picks
about 664 days ago by Fallond_Picks
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ICAD | 0.51 | +0.03 | +6.01% | 25.95M |
| ICA | 6.22 | +0.19 | +3.15% | 930.37M |
| IBOC | 18.67 | +0.17 | +0.92% | 1.245B |
| IBN | 30.14 | +0.85 | +2.92% | 16.88B |
| IBM | 196.55 | +2.25 | +1.16% | 225.13B |
| GTY | 16.26 | +0.05 | +0.31% | 541.25M |
| GTXI | 3.14 | +0.07 | +2.28% | 192.80M |
| GTU | 57.54 | -0.86 | -1.47% | |
| GTSI | 7.73 | -0.01 | -0.13% | 74.69M |
| GTS | 17.69 | -0.10 | -0.56% | 505.77M |
